{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33471528", "DateCompleted": {"Year": "2021", "Month": "03", "Day": "23"}, "DateRevised": {"Year": "2021", "Month": "03", "Day": "23"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "01", "Day": "20"}], "Language": ["eng"], "ELocationID": ["10.1021/acs.jmedchem.0c01707"], "Journal": {"ISSN": "1520-4804", "JournalIssue": {"Volume": "64", "Issue": "3", "PubDate": {"Year": "2021", "Month": "Feb", "Day": "11"}}, "Title": "Journal of medicinal chemistry", "ISOAbbreviation": "J Med Chem"}, "ArticleTitle": "Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design.", "Pagination": {"StartPage": "1558", "EndPage": "1569", "MedlinePgn": "1558-1569"}, "Abstract": {"AbstractText": ["Potent inhibitors of ALK are highly desired because of the occurrence of drug resistance. We herein firstly report the development of a rationally designed inhibitor, <b>Con B-1</b>, which can covalently bind to Cys1259, a cysteine located outside the ALK active site by linking a warhead with Ceritinib through a 2,2'-Oxybis(ethylamine) linker. The <i>in vitro</i> and <i>in vivo</i> assays showed <b>ConB-1</b> is a potent selective ALKi with low toxicity to normal cells. In addition, the molecule showed significant improvement of anticancer activities and potential antidrug resistant activity compared with Ceritinib, demonstrating the covalent inhibitor of ALK can be a promising drug candidate for the treatment of NSCLC. This work may provide a novel perspective on the design of covalent inhibitors."]}, "AuthorList": [{"Identifier": ["0000-0002-3953-6190"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}, {"Identifier": [], "Affiliation": "Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, 450000, China."}], "LastName": "Yan", "ForeName": "Guoyi", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Zhong", "ForeName": "Xinxin", "Initials": "X"}, {"Identifier": ["0000-0003-4892-1979"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Pu", "ForeName": "Chunlan", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Yue", "ForeName": "Lin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Shan", "ForeName": "Huifang", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Lan", "ForeName": "Suke", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Ministry of Education & State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550000, China."}], "LastName": "Zhou", "ForeName": "Meng", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Xinxiang Medical University, Xinxiang, 453000, China."}], "LastName": "Hou", "ForeName": "Xueyan", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Yang", "ForeName": "Jie", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, 450000, China."}], "LastName": "Li", "ForeName": "Deyu", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University, Beijing, 100000, China."}], "LastName": "Fan", "ForeName": "Shilong", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China."}], "LastName": "Li", "ForeName": "Rui", "Initials": "R"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Med Chem", "NlmUniqueID": "9716531", "ISSNLinking": "0022-2623"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfones"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ALK protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Anaplastic Lymphoma Kinase"}, {"RegistryNumber": "K418KG2GET", "NameOfSubstance": "ceritinib"}, {"RegistryNumber": "K848JZ4886", "NameOfSubstance": "Cysteine"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Anaplastic Lymphoma Kinase"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Catalytic Domain"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cysteine"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Resistance, Neoplasm"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": [], "DescriptorName": "Models, Molecular"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Pyrimidines"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Sulfones"}, {"QualifierName": [], "DescriptorName": "Xenograft Model Antitumor Assays"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2021", "Month": "1", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "20", "Hour": "17", "Minute": "8"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33471528", "10.1021/acs.jmedchem.0c01707"]}}], "PubmedBookArticle": []}